Humacyte, Inc. — Director's Dealing 2024

Dec 20, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Humacyte, Inc. (HUMA)
CIK: 0001818382
Period of Report: 2024-12-19

Reporting Person: Prichard Heather Ledbetter (Chief Operating Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-12-19	Stock Options (right to buy)	$10.28	A	525	Acquired	2030-12-14	Common Stock (525)	Direct

Footnotes

F1: On December 14, 2020, Humacyte granted options to purchase 2,625 shares of common stock, which vested as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application ("BLA") to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Humacyte previously reported three-fifths of the option grant on a Form 4 filed on August 27, 2021 and one-fifth of the option grant on a Form 4 filed on December 12, 2023. On December 19, 2024, Humacyte received FDA approval for its acellular tissue engineered vessel product candidate for an indication in vascular trauma. Accordingly, columns 5 and 7 of Table II report the number of securities equal to the final one-fifth of the 12/14/2020 option grant.